LINCOLN, Neb. / Feb 01, 2024 / Business Wire / National Research Corporation (NASDAQ:NRC) today announced that it will provide an online web simulcast of its 2023 fourth quarter and year-end earnings conference call on Wednesday, February 14, 2024. The Company’s results for the 2023 fourth quarter will be released after the close of the market on Tuesday, February 13, 2024.
The live broadcast of National Research Corporation’s conference call will begin at 11:00 a.m. Eastern Time on February 14, 2024. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
A live audio webcast can be accessed at https://events.q4inc.com/attendee/823574505. The webcast will also be available for replay.
For more than 40 years, NRC Health has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it., or visit www.nrchealth.com.
Last Trade: | US$17.76 |
Daily Change: | -0.08 -0.45 |
Daily Volume: | 50,447 |
Market Cap: | US$417.000M |
October 25, 2024 August 22, 2024 August 06, 2024 May 07, 2024 February 13, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB